科济生物医药（上海）有限公司 Mediaroom

CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B

SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2025-11-03 22:15 1561

CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025

SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2025-10-20 08:15 1157

Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia

SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Primary plasma cell leukemia (pPCL) is a rare and highly ag...

2025-10-19 14:00 1503

CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology

SHANGHAI, Oct. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2025-10-08 08:15 1254

CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025

SHANGHAI, Sept. 17, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK...

2025-09-18 08:15 1952

CARsgen Therapeutics Announces 2025 Interim Results

SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2025-08-15 08:15 2625

CARsgen Therapeutics Announces 2025 Interim Results

CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO

SHANGHAI, July 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2025-07-14 08:00 1516

CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting

SHANGHAI, June 1, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2025-06-02 08:15 1742

CARsgen's Satri-cel Granted Priority Review by the NMPA

SHANGHAI, May 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2025-05-28 12:10 1864

CARsgen's Satri-cel Abstract Available on ASCO Website

SHANGHAI, May 22, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2025-05-23 08:00 2092

CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy

SHANGHAI, May 11, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2025-05-12 08:00 2174

CARsgen Announced 2024 Annual Results

SHANGHAI, March 18, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK...

2025-03-19 08:15 3243

CARsgen's Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA

SHANGHAI, March 2, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2025-03-03 08:15 2225

CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in a Patient with Autoimmune Disease

SHANGHAI, Feb. 27, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2025-02-28 08:15 2328

CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China

SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK,...

2025-02-25 21:00 2327

CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)

SHANGHAI, Dec. 30, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2024-12-30 21:50 2863

Latest News